The aim of this study is to investigate how many leiomyoma patients are exposed to bisphenol-A (BPA), an endocrine disruptor, and whether the serum concentration of BPA is related to leiomyoma growth. Initially, 128 patients were divided into one control and three leiomyoma groups (mild, moderate and severe) according to the size of the leiomyomas. Serum BPA concentrations were measured by liquid chromatography and mass spectrometry (LC/MS). Nearly two-thirds of leiomyoma patients were exposed to BPA and the range of BPA was from non-detection to 2.603 ng/ml. The mean BPA concentrations in the groups were 1.015 ± 0.775 ng/ml (control), 0.774 ± 0.834 ng/ml (mild), 1.261 ± 0.797 ng/ml (moderate) and 1.244 ± 0.860 ng/ml (severe) (p = 0.158). After recombination into two group, Group 1 (control plus mild) vs. Group 2 (moderate plus severe), higher level was found in Group 2 even with no statistical significance (p = 0.06). In conclusion, about two-thirds of leiomyoma patients were exposed to BPA, but it may not have growth promoting effect on leiomyoma.
- Bisphenol bisphenol-A (BPA)
- Endocrine disruptor
- Liquid chromatography and mass spectrometry (LC/MS)
ASJC Scopus subject areas
- Health, Toxicology and Mutagenesis